Hayashi Takuji, Sekii Yosuke, Katayama Kinzo, Kamoto Akihito, Kakuta Yoichi, Mori Naoki, Itatani Hiroaki, Yoshioka Toshiaki
Nihon Hinyokika Gakkai Zasshi. 2014 Apr;105(2):37-42. doi: 10.5980/jpnjurol.105.37.
We analyzed the efficacy of ethinylestradiol as estrogen therapy on Castration-resistant Prostate Cancer (CRPC).
The study was conducted on 14 patients who were diagnosed as having CRPC and who were being prescribed ethinylestradiol (1.5-2.0 mg/day) with aspirin (100 mg/day) and an LH-RH agonist in our hospital from August 2011.
All patients had already been treated with a combined androgen blockade (CAB), 8 patients had been treated with docetaxel, 9 patients with tegafur-uracil, 4 patients with estramustine phosphate sodium. Age and prostate-specific antigen (PSA) at prescription of ethinylestradiol was 55-85 (median 75.5) and 0.784-508.7 ng/ml (median 4.842 ng/ml). Thirteen patients (92.9%) achieved a decline in PSA, 8 patients (57.1%) achieved a decline in PSA > 50%. Time to progression was 0-18 months (median 7 months), and there were no severe adverse events including venous thromboembolic diseases.
Oral ethinylestradiol administration may have efficacy for CRPC without severe adverse events. Ethinylestradiol may be one of the selective drugs for CRPC patients who do not wish to undergo intravenous chemotherapy or become resistant to docetaxel.
我们分析了炔雌醇作为雌激素疗法治疗去势抵抗性前列腺癌（CRPC）的疗效。
本研究对2011年8月起在我院被诊断为CRPC且正在服用炔雌醇（1.5 - 2.0毫克/天）、阿司匹林（100毫克/天）及促性腺激素释放激素（LH - RH）激动剂的14例患者进行。
所有患者均已接受联合雄激素阻断（CAB）治疗，8例患者接受过多西他赛治疗，9例患者接受过替加氟 - 尿嘧啶治疗，4例患者接受过磷酸雌莫司汀治疗。开始服用炔雌醇时的年龄和前列腺特异性抗原（PSA）分别为55 - 85岁（中位数75.5岁）和0.784 - 508.7纳克/毫升（中位数4.842纳克/毫升）。13例患者（92.9%）PSA下降，8例患者（57.1%）PSA下降超过50%。疾病进展时间为0 - 18个月（中位数7个月），且未出现包括静脉血栓栓塞性疾病在内的严重不良事件。
口服炔雌醇可能对CRPC有效且无严重不良事件。炔雌醇可能是不希望接受静脉化疗或对多西他赛耐药的CRPC患者的选择性药物之一。
